Bayer (BAYN) Receives Buy Rating from Citigroup

Citigroup reaffirmed their buy rating on shares of Bayer (FRA:BAYN) in a research report sent to investors on Thursday.

A number of other equities analysts have also recently issued reports on the stock. Warburg Research set a €121.00 ($144.05) price objective on shares of Bayer and gave the company a neutral rating in a research report on Thursday. JPMorgan Chase & Co. set a €128.00 ($152.38) price objective on shares of Bayer and gave the company a buy rating in a research report on Wednesday. Commerzbank set a €124.00 ($147.62) price objective on shares of Bayer and gave the company a buy rating in a research report on Tuesday. Sanford C. Bernstein set a €131.00 ($155.95) price objective on shares of Bayer and gave the company a buy rating in a research report on Thursday, January 4th. Finally, Barclays set a €100.00 ($119.05) price objective on shares of Bayer and gave the company a sell rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of €122.33 ($145.63).

Shares of Bayer (BAYN) traded down €0.62 ($0.74) during trading hours on Thursday, reaching €104.86 ($124.83). 2,223,938 shares of the company were exchanged. The stock has a market cap of $86,730.00 and a PE ratio of 28.11. Bayer has a one year low of €99.69 ($118.68) and a one year high of €123.82 ($147.40).

TRADEMARK VIOLATION WARNING: “Bayer (BAYN) Receives Buy Rating from Citigroup” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/13/bayer-bayn-receives-buy-rating-from-citigroup.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply